rel-[(3R,4S)-4-phenylpiperidin-3-yl]methanol | 872544-55-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: rel-[(3R,4S)-4-phenylpiperidin-3-yl]methanol
• 英文别名: [(3R,4S)-4-phenylpiperidin-3-yl]methanol
• CAS: 872544-55-3
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: CCYONUQTZTYVFP-VXGBXAGGSA-N

物化性质

• 沸点：
  328.9±35.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 rel-[(3R,4S)-4-phenylpiperidin-3-yl]methanol 在 sodium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 1.0h， 以100%的产率得到trans-tert-butyl 3-(hydroxymethyl)-4-phenylpiperidine-1-carboxylate
  参考文献：
  名称：

  3,4-二取代哌啶的新途径：（-）-帕罗西汀和（+）-非西西汀的正式合成

  摘要：

  使用手性1,4-二氢吡啶作为关键中间体，开发了一种新的3,4-二取代哌啶途径，其合成效用通过（-）-帕罗西汀和（+）-非西西汀的正式合成得到证明。

  DOI：

  10.1016/j.tetlet.2005.10.049
• 作为产物：
  描述：

  methyl (4R)-4-phenyl-1,2,3,4-tetrahydropyridine-5-carboxylate 在 platinum(IV) oxide 氢气 、 sodium methylate 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 反应 32.0h， 生成 rel-[(3R,4S)-4-phenylpiperidin-3-yl]methanol
  参考文献：
  名称：

  3,4-二取代哌啶的新途径：（-）-帕罗西汀和（+）-非西西汀的正式合成

  摘要：

  使用手性1,4-二氢吡啶作为关键中间体，开发了一种新的3,4-二取代哌啶途径，其合成效用通过（-）-帕罗西汀和（+）-非西西汀的正式合成得到证明。

  DOI：

  10.1016/j.tetlet.2005.10.049

文献信息

• PIPERIDINE DERIVATIVE OR SALT THEREOF
  申请人：Hachiya Shunichiro

  公开号：US20100029687A1

  公开（公告）日：2010-02-04

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  【问题】提供一种化合物，可用于治疗钙感受受体（CaSR）参与的疾病，特别是甲状旁腺功能亢进症。【解决方法】发现一种新的哌啶衍生物，其特征在于3位和4位中的一个位置被取代为含有芳基烷基等基团的氨甲基基团，另一个位置被取代为芳基、杂环芳基等，或其盐，具有出色的CaSR激动调节作用，并且具有出色的选择性，具有可能引起药物相互作用的CYP2D6抑制作用。基于以上发现，这种新的哌啶衍生物可用作治疗CaSR参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良、高钙血症等）的治疗剂。
• Piperidine derivative or salt thereof
  申请人：Astellas Pharma, Inc.

  公开号：US08153658B2

  公开（公告）日：2012-04-10

  To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  提供一种可以用于治疗钙感受受体（CaSR）参与的疾病，特别是甲状旁腺功能亢进症的化合物。发现一种新的哌啶衍生物，其特征在于3位和4位之一被取代为氨甲基基团，该氨甲基基团被取代为芳基烷基基团或类似物，另一位置被取代为芳基，杂环芳基或类似物，或其盐，具有出色的CaSR激动调节作用，并且具有出色的选择性，具有可能引起药物相互作用的CYP2D6抑制作用。基于以上发现，这种新的哌啶衍生物可用作治疗CaSR参与的疾病（甲状旁腺功能亢进症，肾性骨营养不良，高钙血症等）的治疗剂。
• Piperidine derivatives having a gastro-intestinal activity
  申请人：BEECHAM GROUP PLC

  公开号：EP0190496A2

  公开（公告）日：1986-08-13

  Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R, and R2 are both hydrogen or together are a bond; R3 and R4 are independently optionally substituted phenyl or naphthyl groups; Rs is a group (CH2)nR6 wherein n is 1 or 2 and R6 is an optionally substituted phenyl or naphthyl group having activity against disorders relating to impaired gastro-intestinal motility, a process and intermediates for their preparation and their use as pharmaceuticals

  式(I)化合物及其药学上可接受的盐： 其中R和R2均为氢或共为键；R3和R4独立地为任选取代的苯基或萘基；Rs为基团(CH2)nR6，其中n为1或2，R6为任选取代的苯基或萘基，对胃肠道运动障碍相关疾病具有活性，制备它们的工艺和中间体以及它们作为药物的用途
• PIPERIDINE DERIVATIVES OR SALTS THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2085383A1

  公开（公告）日：2009-08-05

  [Problem] To provide a compound which can be used for treating diseases in which a calcium sensing receptor (CaSR) participates, particularly hyperparathyroidism. [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or a salt thereof, has an excellent CaSR agonistic regulatory action, and also has excellent selectivity with a CYP2D6 inhibitory action having a possibility of causing drug interaction. Based on the above, this novel piperidine derivative is useful as a therapeutic agent for diseases in which CaSR participates (hyperparathyroidism, renal osteodystrophy, hypercalcemia, and the like).

  [问题]提供一种可用于治疗钙传感受体（CaSR）参与的疾病，特别是甲状旁腺机能亢进的化合物。 [解决方法]发现一种新型哌啶衍生物，其特征在于 3 位和 4 位中的一个被氨甲基取代，另一个被芳基、杂芳基等取代，或其盐具有极好的 CaSR 激动调节作用，同时还具有极好的选择性，具有 CYP2D6 抑制作用，但有可能引起药物相互作用。基于以上所述，这种新型哌啶衍生物可作为治疗剂用于治疗 CaSR 参与的疾病（甲状旁腺功能亢进症、肾性骨营养不良症、高钙血症等）。
• US8153658B2
  申请人：——

  公开号：US8153658B2

  公开（公告）日：2012-04-10